Cantoni L, Maggi G, Mononi G, Preti G
Minerva Med. 1975 May 2;66(33):1581-9.
After a diffuse introductory discussion on S-adenosylmethionine methyltransferase activity, the results of an experimental trial carried out on 70 hospitalized patients with chronic hepatitis either persistent or aggressive, and with hepatic cirrhosis at various degrees, are reported. A first group of patients was treated with SAMe (S-adenosylmethionine) intravenously administered for 20 days at two daily doses of 15 mg. The second group was instead-receiving, still by i.v. route, 20 mg of fructose-1-6-diphosphage sodium salt, as a drug for comparison given twice a day at the doses of 2.5 over a 20 days' period. The protidemia picture and in particular the albuminic fraction, generally altered in all the cases under study, have been rapidly and significantly restored only in the group of patients treated with SAMe this indicating the efficacy of this molecule on the liver function.
在对S-腺苷甲硫氨酸甲基转移酶活性进行了广泛的介绍性讨论之后，报告了一项针对70名住院的持续性或侵袭性慢性肝炎以及不同程度肝硬化患者进行的实验性试验结果。第一组患者接受静脉注射S-腺苷甲硫氨酸（SAMe）治疗，为期20天，每日两次，每次15毫克。第二组则通过静脉途径接受20毫克果糖-1,6-二磷酸钠盐治疗，作为对照药物，在20天内每日两次，每次2.5毫克。在所有研究病例中通常都会改变的蛋白血症情况，尤其是白蛋白部分，仅在接受SAMe治疗的患者组中迅速且显著恢复，这表明该分子对肝功能有疗效。
